Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Name||adenosquamous lung carcinoma|
|Definition||An adenosquamous carcinoma located_in lung that derives_from lung tissue composed of at least 10% by volume each of squamous cell carcinoma (SqCC) and adenocarcinoma (AdC) cells.|
|Path||disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer adenosquamous lung carcinoma|
|Molecular Profile||Therapy||Indication/Tumor Type||Response Type||Profile Response Detail|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03894618||Phase I||SL-279252||SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas||Recruiting||USA | ESP | CAN | BEL||0|
|NCT04173507||Phase II||Avelumab + Talazoparib||Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)||Active, not recruiting||USA||0|